Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings

Neurodegenerative Diseases

Volumn 1, Issue 4-5, 2004, Pages 175-183

  Braungart, Evelyn ^a   Gerlach, Manfred ^b   Riederer, Peter ^b   Baumeister, Ralf ^c,e   Hoener, Marius C ^d  

^a Pieris Pharmaceuticals GmbH   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e Bio3/Bioinfo and Molec Genetics ^*  (Germany)

Author keywords

Caenorhabditis elegans; Dopaminergic neurons; High throughput screenings; MPP+; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; ASCORBIC ACID; CARNITINE; CREATINE; LISURIDE; LITHIUM; NICOTINAMIDE; NICOTINE; NOMIFENSINE; ROTTLERIN; SELEGILINE; THIOCTIC ACID; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAENORHABDITIS ELEGANS; CLINICAL FEATURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG SCREENING; INCUBATION TIME; LETHALITY; MOBILIZATION; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; CAENORHABDITIS ELEGANS; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GREEN FLUORESCENT PROTEINS; MITOCHONDRIA; MOTOR ACTIVITY; NEURONS; PARKINSON DISEASE, SECONDARY; PHENOTYPE; ROTENONE; UNCOUPLING AGENTS;

EID: 9244251118     PISSN: 16602854     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080983     Document Type: Article

References (34)

1. Nass R, Hall DH, Miller DM 3rd, Blakely RD: Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans. Proc Natl Acad Sci USA 2002;99:3264-3269.
2. Gerlach M, Riederer P: Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man. J Neural Transm 1996;103:987-1041.
3. Kindt MV, Heikkila RE: Prevention of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B. Life Sci 1986;38:1459-1462.
4. Russ H, Staust K, Martel F, Gliese M, Schomig E: The extraneuronal transporter for monoamine transmitters exists in cells derived from human central nervous system glia. Eur J Neurosci 1996;8:1256-1264.
5. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH: Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-2177.
6. Mizuno Y, Suzuki K, Sone N, Saitoh T: Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo. Neurosci Lett 1988;91:349-353.
7. Tipton KF, Singer TP: Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993;61:1191-1206.
8. Smith MT, Ekstrom G, Sandy MS, Di Monte D: Studies on the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine cytotoxicity in isolated hepatocytes. Life Sci 1987;40:741-748.
9. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ: A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
10. Herrero MT, Augood SJ, Asensi H, Hirsch EC, Agid Y, Obeso JA, Emson PC: Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTPintoxicated parkinsonian monkeys. Brain Res Mol Brain Res 1996;42:149-155.
11. Taylor JR, Elsworth JD, Roth RH, Sladek JR Jr, Redmond DE Jr: Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997;81:745-755.
12. 18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998;29:225-232.
13. Heikkila RE: Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources. Eur J Pharmacol 1985;117:131-133.
14. Jarvis MF, Wagner GC: Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine. Life Sci 1985;36:249-254.
15. Bradbury AJ, Costall B, Domeney AM, Jenner P, Kelly ME, Marsden CD, Naylor RJ: 1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway. Nature 1986;319:56-57.
16. Frohna PA, Rothblat DS, Joyce JN, Schneider JS: Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism. Synapse 1995;19:46-55.
17. Bargmann CI: Neurobiology of the Caenorhabditis elegans genome. Science 1998;282:2028-2033.
18. Baumeister R, Ge L: The worm in us - Caenorhabditis elegans as a model of human disease. Trends Biotechnol 2002;20:147-148.
19. White JG, Southgate E, Thomson JN, Brenner S: The structure of the nervous system of the nematode Caenorhabditis elegans. Philos Trans R Soc Lond 1986;314:1-340.
20. Sulston J, Dew M, Brenner S: Dopaminergic neurons in the nematode Caenorhabditis elegans. J Comp Neurol 1975;163:215-226.
21. Wintle RF, Van Tol HH: Dopamine signaling in Caenorhabditis elegans-potential for parkinsonism research. Parkinsonism Relat Disord 2001;7:177-183.
22. Wood WB: The Nematode C. elegans. Cold Spring Harbor, Cold Spring Harbor Laboratory, 1988.
23. Lints R, Emmons SW: Patterning of dopaminergic neurotransmitter identity among Caenorhabditis elegans ray sensory neurons by a TGFbeta family signaling pathway and a Hox gene. Development 1999;126:5819-5831.
24. Hobert O, Mori I, Yamashita Y, Honda H, Ohshima Y, Liu Y, Ruvkun G: Regulation of interneuron function in the C. elegans thermoregulatory pathway by the ttx-3 LIM homeobox gene. Neuron 1997;19:345-357.
25. Troemel ER, Kimmel BE, Bargmann CI: Re-programming chemotaxis responses: Sensory neurons define olfactory preferences in C. elegans. Cell 1997;91:161-169.
26. Rohrig S, Rockelein I, Donhauser R, Baumeister R: Protein interaction surface of the POU transcription factor UNC-86 selectively used in touch neurons. EMBO J 2000;19:3694-3703.
27. Song X, Perkins S, Jortner BS, Ehrich M: Cytotoxic effects of MPTP on SH-SY5Y human neuroblastoma cells. Neurotoxicology 1997;18:341-353.
28. Marini AM, Schwartz JP, Kopin IJ: The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells. J Neurosci 1989;9:3665-3672.
29. Sanchez-Ramos JR, Song S, Facca A, Basit A, Epstein CJ: Transgenic murine dopaminergic neurons expressing human Cu/Zn superoxide dismutase exhibit increased density in culture, but no resistance to methylphenylpyridinium- induced degeneration. J Neurochem 1997;68:58-67.
30. Sawin ER, Ranganathan R, Horvitz HR: C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron 2000;26:619-631.
31. Jenner P, Marsden CD: The actions of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine in animals as a model of Parkinson's disease. J Neural Transm Suppl 1986;20:11-39.
32. Olanow CW: The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 2002;58:S33-41.
33. Schafer WR, Kenyon CJ: A calcium-channel homologue required for adaptation to dopamine and serotonin in Caenorhabditis elegans. Nature 1995;375:73-78.
34. Kamath RS, Fraser AG: Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003;421:231-237.